c-MET NSCLC FDA Approvals, Clinical Trials Assessment, Pipeline Insights, and Companies ...
DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...
Promising Clinical Developments and Strategic Collaborations Justify Buy Rating for Nurix ...
Nurix Therapeutics (NRIX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...
J.P. Morgan Keeps Their Buy Rating on Nurix Therapeutics (NRIX)
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $30.00.